CN111138553A - Fusion protein, toxoplasma subunit vaccine and vaccine composition thereof - Google Patents
Fusion protein, toxoplasma subunit vaccine and vaccine composition thereof Download PDFInfo
- Publication number
- CN111138553A CN111138553A CN202010051245.2A CN202010051245A CN111138553A CN 111138553 A CN111138553 A CN 111138553A CN 202010051245 A CN202010051245 A CN 202010051245A CN 111138553 A CN111138553 A CN 111138553A
- Authority
- CN
- China
- Prior art keywords
- toxoplasma
- vaccine
- protein
- fusion protein
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 71
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 40
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 241000223996 Toxoplasma Species 0.000 title claims description 38
- 229940031626 subunit vaccine Drugs 0.000 title claims description 22
- 101000871081 Toxoplasma gondii Dense granule protein 3 Proteins 0.000 claims abstract description 44
- 239000002773 nucleotide Substances 0.000 claims abstract description 19
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 17
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 16
- 206010000210 abortion Diseases 0.000 claims abstract description 12
- 231100000176 abortion Toxicity 0.000 claims abstract description 12
- 102000002067 Protein Subunits Human genes 0.000 claims abstract description 5
- 241000223997 Toxoplasma gondii Species 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 108010049895 Toxoplasma SAG1 antigen Proteins 0.000 claims description 12
- 108091026890 Coding region Proteins 0.000 claims description 6
- 206010057179 Toxoplasma infections Diseases 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 abstract description 24
- 201000005485 Toxoplasmosis Diseases 0.000 abstract description 20
- 230000005847 immunogenicity Effects 0.000 abstract description 11
- 108010001267 Protein Subunits Proteins 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 84
- 102000004169 proteins and genes Human genes 0.000 description 49
- 241000282898 Sus scrofa Species 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 238000010353 genetic engineering Methods 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 241000282887 Suidae Species 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 210000003000 inclusion body Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000000568 immunological adjuvant Substances 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000012880 LB liquid culture medium Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001571 immunoadjuvant effect Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010062343 Congenital infection Diseases 0.000 description 1
- 201000007045 Congenital toxoplasmosis Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010036595 Premature delivery Diseases 0.000 description 1
- 102100038358 Prostate-specific antigen Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000000059 tachyzoite Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/45—Toxoplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides a fusion protein and a nucleotide sequence thereof, which comprise a toxoplasma gondii P30 protein subunit and a T cell epitope. And a vaccine composition thereof for preventing abortion of a pregnant sow due to toxoplasmosis using the fusion protein. The invention has the advantages that the fusion protein has the characteristics of high expression quantity and high immunogenicity. The vaccine and the vaccine composition can effectively prevent abortion of pregnant sows caused by toxoplasmosis, and have high vaccine stability.
Description
Technical Field
The invention relates to the fields of immunology and biology, in particular to a swine toxoplasma gondii genetic engineering subunit vaccine, a preparation method and application thereof, and mainly relates to a nucleotide sequence, a fusion protein, a vaccine for the swine toxoplasma gondii vaccine, a preparation method and application thereof.
Background
Toxoplasmosis, also known as toxoplasmosis or toxoplasmosis, is a worldwide distributed parasitic disease of humans and animals caused by the Toxoplasma gondii (Toxoplasma gondii), widely spread in humans, animals and wild animals, and seriously threatens the public health of humans and animals. Toxoplasma gondii can infect more than 200 vertebrates. According to foreign reports, the average infection rate of people is 25-50%, and at least 5 hundred million people in the world are predicted to be infected with toxoplasma gondii by people. According to statistics, the infection rate of toxoplasma of residents in China is 0.1-47.3%. The toxoplasma infection rate of pigs in China is 4.78-85.7%, the infection rate of cattle is 0.2-43.4%, and the infection rate of sheep is 0.35-37%. Seriously affecting the human health and the development of animal husbandry.
The infection of the toxoplasma gondii in the pregnant women can affect the development of fetuses, and even cause teratogenesis and even death of serious people, and meanwhile, the pregnant women suffer abortion or premature delivery; toxoplasma gondii is a major opportunistic causative agent in immunosuppressed or immunodeficient patients. It is reported that 30-46% of pregnant women have a chance to transmit toxoplasma to the fetus after infecting it, causing congenital infection of the fetus, resulting in abortion, stillbirth or congenital toxoplasmosis; 6-10% of AIDS patients are complicated by toxoplasmosis, and 50% of encephalitis of AIDS patients are caused by toxoplasmosis infection. The positive rate of toxoplasma antibody of pregnant and lying-in women and tumor patients is as high as 10-60%. The pig infected with toxoplasma also can cause 'innominate hyperpyrexia', and the fatality rate reaches 60%. The dog and cat as companion animals lift a crowd of 'pet fever of dog and cat', the dog as an important intermediate host of toxoplasma, and the cat as a unique terminal host is closely contacted with human and becomes a main infection source of human toxoplasmosis.
So far, no ideal commercial vaccine and medicine for preventing and treating toxoplasmosis exists at home and abroad, and host protective immune response can be caused after the toxoplasmosis is infected, so that the development of safe and effective vaccine is a good prevention measure for the toxoplasmosis. The development of toxoplasma gondii vaccines has gone through several stages, including whole worm vaccines, subunit vaccines, genetically engineered vaccines and nucleic acid (or DNA) vaccines, since the 60 s. Whole worm vaccines include inactivated vaccines and attenuated live vaccines, but the inactivated vaccines lack immunoprotection for mice, so that the whole worm vaccines have no practical application value; toxoplasma tachyzoite is weakened in toxicity after being treated by ultraviolet rays, radioactive rays, chemical reagents and the like, and can induce stronger immune response such as Ts-4, T-263 and S48, but attenuated live vaccines have the risks of insufficient attenuation, reversion of toxicity and the like, so that attenuated live vaccines cannot be widely used; the subunit vaccine is prepared by extracting specific components from a lysate of an insect body or an excretion-secretion antigen, has good immunogenicity, but is time-consuming and labor-consuming in purification and expensive in price; the gene engineering subunit vaccine is to express toxoplasma antigen gene in high efficiency expression vector to obtain great amount of purified single antigen. The above discussion can find that the genetic engineering vaccine is hope for the development of the toxoplasma vaccine and has potential development and application values.
Disclosure of Invention
The invention aims to provide a fusion protein capable of preventing a pig from being infected with a toxoplasma epidemic disease and a vaccine composition thereof. The invention also provides pharmaceutical compositions, such as vaccine compositions, containing the fusion proteins. In addition, the invention also provides a nucleotide for encoding the fusion protein, a method for preparing the fusion protein and the like.
Aiming at the current problems, the invention provides a nucleotide sequence, a vector, a protein, a vaccine, a preparation method and application thereof for preventing pig toxoplasma infection, wherein a toxoplasma P30 mutant gene is artificially synthesized (the artificially synthesized toxoplasma P30 mutant gene provided by the invention is the gene of the toxoplasma P30 epitope mutant in the invention), the P30 mutant gene is transferred into engineering bacteria for expression, the recombinant antigen is efficiently expressed after induction, and the genetic engineering vaccine with ideal immunogenicity is obtained through processes of fermentation, purification, emulsification and the like, so that the epidemic of the pig toxoplasma epidemic disease can be prevented.
One of the objectives of the present invention is to provide a novel vaccine polypeptide and a vaccine composition thereof, which can be used for preventing swine toxoplasma gondii.
The second purpose of the invention is to provide a construction and obtaining method of the protein genetic engineering vaccine.
The invention also aims to provide a genetic engineering strain capable of expressing the swine toxoplasma gondii genetic engineering subunit vaccine.
The fourth purpose of the invention is to provide a preparation method of the swine toxoplasma gondii genetic engineering subunit vaccine.
The fifth purpose of the invention is to provide the pig genetic engineering subunit vaccine which can induce humoral immune response in the body of an immune target animal.
In the first aspect, the invention provides a novel vaccine polypeptide capable of preventing swine toxoplasma and a vaccine composition thereof, wherein the vaccine polypeptide contains a mutant of a toxoplasma conserved structural gene P30 (the toxoplasma P30 mutant gene provided by the invention, namely the toxoplasma P30 epitope mutant gene), the 1 st to 480 th nucleotides of the toxoplasma P30 gene are analyzed by using a molecular biology software DNAstar, and the sequence of the toxoplasma P30 gene is subjected to 17-nucleotide point mutation and modification. The toxoplasma P30 mutant gene was followed by a T cell epitope. The protein engineering vaccine for preventing the swine toxoplasma provided by the invention contains non-immune active substances besides main immunogenic proteins. The nonimmunogenic substances include mainly a purification tag and C-terminal polyadenylic acid. Pharmaceutically acceptable salts are those which are non-toxic, irritating and allergenic and are suitable for use in human or animal tissues. Inactive substances and pharmaceutically acceptable salts are well known to those skilled in the art. Preferably, the adjuvant is 206 adjuvant; the antigen protein buffer solution is PBS; the purification tag and the C-terminal polynucleotide are carried on a vector, and the purification tag and the C-terminal polynucleotide carried on pET-28a are preferred.
In a second aspect, the present invention provides a nucleotide molecule encoding a swine toxoplasma genetically engineered subunit vaccine protein according to the first aspect of the present invention. The nucleotide can be in a DNA form, is synthesized by an artificial synthesis mode, is subjected to gene engineering operation, is cloned into a vector, is transformed into escherichia coli, and is screened, fermented and purified to obtain the swine toxoplasma vaccine polypeptide. The nucleic acid may be subjected to conventional molecular biological procedures in the present invention, such as: PCR, restriction enzyme digestion, ligation, etc. Nucleic acid design 5 'end and 3' end both add enzyme cutting sites, the gene manipulation technology is known to the technicians in this field.
In a third aspect, the present invention provides a vector comprising, in addition to the nucleotide molecule encoding the amino acids of the genetically engineered subunit vaccine of swine toxoplasma according to the second aspect of the present invention, expression control elements operably linked to the nucleotide sequence required for expression (transcription and translation) in prokaryotic cells. The most basic expression control elements include promoters, transcription terminators, enhancers, selectable markers, and the like, and these control elements are well known in the art. In a preferred embodiment, the expression vector is an E.coli expression vector.
In a fourth aspect, the invention provides a host cell, preferably E.coli. Comprising a vector according to the third aspect of the invention. The host cell is transformed or transfected with a gene sequence containing the coding protein, and then the gene sequence is detected to have good heredity and expression stability, so that the gene sequence can be used for producing the required swine toxoplasma protein engineering vaccine through fermentation expression.
In a fifth aspect, the invention provides a preparation method of a swine toxoplasma protein engineering vaccine, which comprises the following steps: the engineering bacteria ferment and express protein engineering vaccine protein, and the required protein is obtained through a purification process and a subsequent emulsification process. The methods involved include, but are not limited to, cell disruption, inclusion body washing, centrifugation, affinity chromatography, hydrophobic chromatography, emulsification, etc. The preparation processes involved in the present invention are well known to those skilled in the art.
In a sixth aspect, the present invention provides a vaccine for preventing toxoplasmosis in pigs, comprising the protein of the first aspect of the invention and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is an immunopotentiator or an immunoadjuvant, and preferably the immunoadjuvant is 206 adjuvant.
In a seventh aspect, the invention provides the use of the protein engineered vaccine of the sixth aspect. The vaccine can be injected into an immune pig through muscle injection, intradermal injection or subcutaneous injection with a certain effective dose, and can stimulate the humoral immune response and the cellular immunity of an organism.
The invention provides a fusion protein, which comprises a toxoplasma gondii P30 protein subunit and also comprises a T cell epitope. T cell epitope obviously improves the immunogenicity of the fusion protein.
Preferably, the toxoplasma gondii P30 protein subunit is a toxoplasma gondii P30 epitope mutant, and the amino acid sequence of the toxoplasma gondii P30 epitope mutant is the amino acid sequence shown in Seq ID NO. 2. The invention intercepts 160 amino acids (shown in Seq ID NO: 2) of the toxoplasma gondii P30 protein subunit and uses the amino acids as the toxoplasma gondii P30 epitope mutant for constructing the fusion protein, compared with the prior art, the obtained fusion protein is soluble expressed and is not expressed in an inclusion body, the expression quantity of the fusion protein is effectively improved, and meanwhile, the immunogenicity of the toxoplasma gondii P30 epitope mutant is kept.
Preferably, in any of the above cases, the amino acid sequence of the T cell epitope is the amino acid sequence shown in Seq ID No. 4. The T cell epitope sequence selected by the invention is firstly used for preparing fusion protein vaccines, particularly for preparing swine toxoplasmosis vaccines, and has the functions of improving the immunogenicity of toxoplasmosis P30 epitope mutants, simultaneously enabling the toxoplasmosis P30 epitope mutants-T cell epitope fusion protein to be efficiently expressed, and the obtained fusion protein is soluble expression and is not expressed in inclusion bodies.
Preferably, in any of the above, the coding sequence of the Toxoplasma gondii P30 epitope mutant comprises the nucleotide sequence shown in Seq ID No. 1. The invention intercepts 1-480 bases of a Toxoplasma gondii P30 gene, codon optimization is carried out on the gene in order to improve the protein expression quantity, 17 bases are mutated in total, and the gene is called a P30 mutant gene, namely the Toxoplasma gondii P30 epitope mutant gene.
Preferably, in any of the above, the coding sequence for the T cell epitope comprises the nucleotide sequence of the T cell epitope represented by Seq ID No. 3.
Preferably, in any of the above, the fusion protein comprises 1 Toxoplasma gondii P30 epitope mutant and 1T cell epitope. It is further preferred that the last amino acid of the mutant toxoplasma P30 epitope is directly linked to the first amino acid of the T cell epitope and that the last amino acid of the mutant toxoplasma P30 epitope does not comprise any linking amino acids to the first amino acid of the T cell epitope.
The fusion protein of any one of the above mentioned items, vaccine polypeptide for preventing swine toxoplasma and vaccine composition thereof, swine toxoplasma gene engineering subunit vaccine protein, swine toxoplasma gene engineering subunit vaccine, swine toxoplasma protein engineering vaccine, vaccine for preventing swine toxoplasmosis.
The invention also provides a nucleic acid molecule encoding the fusion protein of any one of the above.
Preferably, the coding sequence of the nucleic acid molecule comprises the nucleotide sequence set forth in Seq ID No. 5.
Preferably in any of the above, the amino acid sequence of the nucleic acid molecule is the amino acid sequence of Seq ID No. 6.
The invention also provides a toxoplasma subunit vaccine and a vaccine composition thereof, which comprise the amino acid sequence of the fusion protein and/or the nucleic acid molecule.
Preferably, the toxoplasma subunit vaccine and the compositions thereof are used as vaccines for preventing abortion of pregnant sows due to toxoplasma infection.
The fusion gene of the swine toxoplasma gene engineering subunit vaccine is divided into two parts, wherein the first part comprises: intercepting 1 st to 480 th bases of a Toxoplasma gondii P30 gene, carrying out codon optimization on the gene in order to improve the protein expression quantity, and mutating 17 bases in total, wherein the gene is called a P30 mutant gene; a second part: selecting a T cell epitope, splicing the two genes together to form a P30 fusion gene, inserting the gene into an escherichia coli expression vector for expression and purification to obtain a recombinant fusion protein, and adding an adjuvant to prepare the swine toxoplasma gondii genetic engineering subunit vaccine. Can be used for preventing sow abortion caused by toxoplasma infection. Preferably, the vaccine composition further comprises an inactive substance and a pharmaceutically acceptable salt, further preferably, the vaccine composition comprises an immunological adjuvant, and further preferably, the immunological adjuvant is 206 adjuvant.
In the prior art, toxoplasma vaccines have not been successfully marketed. Toxoplasma gondii has many types of types, each of which is classified into many types, either genotypes or serotypes, and there are various isolates under each serotype or genotype, like other bacteria or viruses. However, different genotypes of different isolates have differences, so that in the existing scientific research, the types of the antigen fragments which can be used for preparing the toxoplasma vaccine are very many, and the length of the antigen fragments is selected differently, so that the selection of the antigen fragments in different researches is random, whether good effects can be achieved or not needs to be verified according to the result of the final immune animal. In the invention, in the selection of countless antigen fragments, the toxoplasma gondii P30 antigen epitope mutant provided by the invention is selected, and the prepared vaccine can effectively protect animals through experimental verification and can be preferably used as a vaccine for preventing swine toxoplasmosis.
The invention has the beneficial technical effects that the toxoplasma gondii P30 epitope mutant-T cell epitope fusion protein, the vaccine for preventing abortion of pregnant sows caused by toxoplasmosis and the vaccine composition thereof are provided, compared with the prior art, the fusion protein can be expressed in a soluble way in bacterial liquid supernatant, does not form inclusion bodies, and has the characteristics of high expression quantity and high immunogenicity. The vaccine and the vaccine composition can effectively prevent abortion of pregnant sows caused by toxoplasmosis, and have high vaccine stability.
Drawings
FIG. 1 shows the result of the amplification of the fusion gene of Toxoplasma gondii P30 epitope mutant gene and T cell epitope gene.
FIG. 2 shows the SDS-PAGE result of the recombinant expression protein of the Toxoplasma gondii P30 fusion gene.
FIG. 3 shows the SDS-PAGE result of protein purification of recombinant expression of Toxoplasma gondii P30 fusion gene.
FIG. 4 Western blot result of recombinant expression protein of toxoplasma gondii P30 fusion gene.
FIG. 5 Toxoplasma gondii P30 recombinant fusion protein stimulated mouse RAW264.7 cells to produce TNF- α levels.
FIG. 6. Toxoplasma gondii P30 recombinant fusion protein stimulated IL-12 production by mouse dendritic cells.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to the following embodiments, and it should be understood that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. In the following examples, unless otherwise specified, all methods are conventional. The reagents, vectors, cells and cells used are commercial products well known in the art unless otherwise specified.
Example 1: construction of prokaryotic expression vector of toxoplasma recombinant protein
Primers were designed with reference to the open reading frame of the Toxoplasma gondii P30 gene sequence and the physical map of the prokaryotic expression vector pET28a and the restriction sites BamH I and Hind III were introduced.
Upstream: GGATCCatgtcggtttcgctgcacca
Downstream: AAGCTTtggctcctttggaaag
In Escherichia coli, under the general condition, protein expression with larger molecular weight generally exists in the form of inclusion body, codons of natural sequence are not favorable for expression in Escherichia coli, codon optimization is needed to be carried out to be favorable for the preference of an Escherichia coli expression system, meanwhile, in the research process of the invention, the main epitope of P30 gene is mainly located in the first 480 nucleotides (namely, compared with the full-length P30 gene in the prior art, the invention provides a shorter nucleotide sequence containing the main epitope of P30 gene, and the protein obtained therefrom is proved to have immunogenicity in the subsequent research), so that the DNA star software analysis is carried out to carry out codon optimization, 17-nucleotide point mutation is carried out (it is required to point out that although the sequence optimization by the software analysis is a conventional technical means, but is clear for a person skilled in the art, the sequence analysis is only a conjecture which is obtained by the software analysis and is not necessarily capable of ensuring the soluble expression of the protein, the obtained protein can not be ensured to be capable of retaining the immunogenicity, the obtained protein can be obtained by the result that the gene expression of the gene is carried out after the PCR amplification of the gene sequence of the plasmid DNA star DNA plasmid DNA 60, the plasmid DNA 70, the plasmid DNA 70, the plasmid DNA 70, the plasmid DNA 70 plasmid DNA 70, the plasmid DNA 70, the plasmid DNA.
Example 2: expression and purification of expressed proteins
(1) Extraction and solubility verification of expressed protein
The E.coli BL21(DE3) single colony transformed with recombinant plasmid pET-28a-P30 is used as an engineering strain of swine toxoplasma vaccine (BL21(DE3) -pET-P30), the E.coli BL21(DE3) single colony transformed with pET-28a empty vector is used as a blank control strain (BL21(DE3) -pET-28a), and the two strains are respectively inoculated in 8mL LB liquid culture medium and cultured with shaking overnight at 37 ℃. Transferring the seed solution to 400mL LB liquid culture medium for propagation at 37 ℃, adding IPTG (isopropyl-beta-thiogalactoside) with the final concentration of 0.1Mm/L when the OD600 of the bacterial solution is monitored to be 0.6-0.7, and carrying out induced expression for 16 hours under the optimal condition of 18 ℃. And (3) centrifugally collecting thalli, suspending the thalli by using 10mL of soluble protein lysate, adding 100 mu L of 0.1M PMSF, repeatedly freezing and thawing for 3 times (-80 ℃,1h/37 ℃ and 10min), then carrying out ultrasonic treatment, or adding 100 mu L of DNase, 100 mu L of 100 XDNase Buffer and 100 mu L of LRNase, carrying out water bath at 37 ℃ for 15min, and centrifugally taking supernatant to obtain the soluble protein (protein with activity). The two supernatants were subjected to SDS-PAGE to verify the expression of the target protein of the engineered vaccine strain, as shown in FIG. 2, the engineered strain of the swine toxoplasma vaccine expressed the target protein at around 19KD, while the blank control did not, as shown in FIG. 2: m, protein marker; 1, BL21(DE3) -pET-28a blank; 2, BL21(DE3) -pET-P30.
(2) Purification of fusion expressed proteins
Adding 2mL of 50% Ni-NTA suspension into 10mL of cracking supernatant containing the protein, and slowly shaking for 1-2h on a rotary shaker at the rotating speed of 200 rpm; the entire suspension was poured into a column with a bottom cap and a cap (QIAGEN), the bottom cap was opened, the column was gently pressed down with the cap, the cap was removed, the liquid was allowed to drip slowly by gravity, and the effluent suspension was collected for SDS-PAGE to determine whether any unbound protein was present. Washing the column filled with Ni-NTA with lysis solution, 1mL each time, detecting the concentration of protein at OD280 with a NanodROP1000spectrophotometer, and repeatedly washing until no protein is detected; after the washing liquid is changed, washing the Ni-NTA column by the same method, and detecting the protein concentration by using NANODROP; when the protein can not be detected, dissolving the protein by using a protein dissolving solution, loading 0.5mL of the protein into a column every time, collecting the solution flowing out every time into a new 1.5mL centrifuge tube, dissolving the protein which is the purified expression protein until the protein can not be detected by using NANODROP, detecting the protein purity by SDS-PAGE, detecting the protein concentration by using a BCA protein detection kit, wherein the concentration is 5.3mg/mL, and the result is shown in figure 3: m, protein marker; 1, recombinant P30 fusion protein (Toxoplasma gondii P30 epitope mutant-T cell epitope fusion protein).
Example 3: western blot identification
The western blot identification is carried out on the fusion protein induced and expressed by BL21(DE3) -pET-P30 engineering bacteria by using dog toxoplasma positive serum as a primary antibody, rabbit anti-dog IgG labeled by horseradish peroxidase as a secondary antibody and DAB as a substrate color developing agent. BL21(DE3) -pET-28a served as a negative control. The results are shown in FIG. 4, FIG. 4: m: pre-dyeing a Marker III; 1, BL21(DE3) -pET-P30; 2, BL21(DE3) -pET-28 a. .
Example 4: detection of immunogenicity of mouse macrophage by expression product
RAW264.7 cells were cultured at 0.5X 106Perml was inoculated into 24-well plates, 1mL per well, 5% CO2And culturing at 37 ℃ for 24 h. After the supernatant is sucked out, the prepared toxoplasma recombinant P30 mutant protein (toxoplasma P30 epitope mutant-T cell epitope fusion protein) is dissolved in RAW264.7 cell culture solution and added into a cell culture plate according to the concentration of 1 mu g/mL, 0.1 mu g/mL and 0.01 mu g/mL and according to the concentration of 1 mL/well, and the equal volume of blank plasmid purified protein NR is used as a negative control in the experiment. Place the cell culture plate in 5% CO2And culturing in an incubator at 37 ℃ for 48 hours, collecting supernatant, and detecting the TNF-a level by an ELISA experiment. The results showed that the extent of TNF-a production varied and that the amount of TNF-a increased with increasing protein concentration, ranging from 180pg to 520pg, and are shown in FIG. 5; the results show that the recombinant protein can stimulate the TNF-a production of RAW264.7 cells.
Example 5 detection of immunogenicity of expression products to mouse dendritic cells
Separating mouse dendritic cell, regulating cell concentration to 0.5 × 106one/mL, seeded into 48 well tissue culture plates, 0.5mL per well. The treated recombinant protein (Toxoplasma gondii P30 epitope mutant-T cell epitope fusion protein) was added to the cell culture at concentrations of 1. mu.g/mL, 0.1. mu.g/mL, and 0.01. mu.g/mL, respectivelyAnd (5) cultivating the plates. Place the cell culture plate in 5% CO2And culturing at 37 ℃ in an incubator for 24 hours, collecting culture supernatant, and detecting the IL-12 level in the supernatant through an ELISA experiment. The results show that each group produces different IL-12 content and presents protein concentration dependence, the results are shown in FIG. 6, and the results show that the recombinant protein can stimulate dendritic immune cells of mice to produce a large amount of IL-12.
Example 6: preparation of vaccines
The purified P30 fusion protein antigen (Toxoplasma gondii P30 epitope mutant-T cell epitope fusion protein) is filtered by a 0.22 micron sterilization filter into an autoclaved bag body. Diluted to 600. mu.g/ml with sterile 0.01mol/L PBS (pH 7.4). Adjuvant 206 was filled into another emulsion tank and autoclaved at 121 ℃ for 40 minutes. The antigen protein is injected into the emulsification tank by using compressed air, and the ratio of the water phase to the oil phase is 50: 50. And (3) setting emulsification conditions: stirring was carried out at 30 ℃ and a stirring speed of 100rpm for 2 hours. The vaccine is qualified by aseptic inspection, the content of endotoxin is lower than 100 EU/first part, the emulsified vaccine is centrifuged for 1min at 12000rpm, and the layering phenomenon of the vaccine appears, which indicates that the stability of the vaccine is good.
Example 7 study of Toxoplasma recombinant subunit vaccine in mammalian applications
20 pigs (2-3 years old) pregnant for 1 month are divided into 2 groups, the first group is 10 pigs, the P30 experimental group (adjuvant is 206 adjuvant, 200 mug/pig, intramuscular injection) and the second group is 10 pigs, the negative control group (blank expression vector purified protein with equal volume amount, matched with 206 adjuvant, intramuscular injection) are provided, each group is injected three times and three weeks are provided. Week 10 intravenous injection of purified Toxoplasma trophozoite 104The abortion protection status of the pigs was recorded daily for each individual, and the results are shown in table 1.
TABLE 1 protective Effect of recombinant Toxoplasma gondii P30 fusion protein on test animals (swine) after immunization
Grouping | Immunological pathways | Number of immunizations (times) | Rate of protection |
206 adjuvant vaccine group | Intramuscular injection | 3 | (9/10)90% |
Negative control group | Intramuscular injection | 3 | (0/10)0% |
The results show that 9 of the 10 pregnant sows did not suffer abortion and only 1 of the 10 pregnant sows did suffer abortion in the 206 vaccine group after challenge. After the negative control group had been challenged, 10 pregnant sows all had miscarriages.
By combining the experimental results, the swine toxoplasma gondii genetic engineering subunit vaccine provided by the invention can be used as a vaccine for preventing toxoplasmosis of pregnant sows.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention. None of the chemical agents used in the present invention are commercially available ski agents such as sigmaaldrich. The experimental techniques used are described in the handbooks of molecular cloning, and the like, unless otherwise specified.
Claims (10)
1. A fusion protein comprising a toxoplasma P30 protein subunit, wherein the fusion protein further comprises a T cell epitope.
2. The fusion protein of claim 1, wherein the subunit of the Toxoplasma gondii P30 protein is a Toxoplasma gondii P30 epitope mutant, and the amino acid sequence of the Toxoplasma gondii P30 epitope mutant is the amino acid sequence shown in Seq ID No. 2.
3. The fusion protein of claim 1, wherein the amino acid sequence of the T cell epitope is the amino acid sequence of SeqID NO. 4.
4. The fusion protein of claim 1, wherein the coding sequence for the Toxoplasma gondii P30 epitope mutant comprises the nucleotide sequence set forth in Seq ID No. 1.
5. The fusion protein of claim 1, wherein the coding sequence for the T cell epitope comprises the nucleotide sequence of the T cell epitope represented by SeqID No. 3.
6. A nucleic acid molecule encoding the fusion protein of any one of claims 1-5.
7. The nucleic acid molecule of claim 6, wherein the coding sequence of said nucleic acid molecule comprises the nucleotide sequence set forth in Seq ID No. 5.
8. The nucleic acid molecule of claim 6, wherein the amino acid sequence of said nucleic acid molecule is the amino acid sequence of Seq ID No. 6.
9. A Toxoplasma gondii subunit vaccine and vaccine compositions thereof, comprising the amino acid sequence of the fusion protein of any one of claims 1-5 and/or the nucleic acid molecule of any one of claims 6-8.
10. The toxoplasma subunit vaccine and vaccine composition thereof of claim 9, wherein the toxoplasma subunit vaccine and composition thereof is a vaccine for preventing abortion in pregnant sows due to toxoplasma infection.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010051245.2A CN111138553B (en) | 2020-01-17 | 2020-01-17 | Fusion protein, toxoplasma subunit vaccine and vaccine composition thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010051245.2A CN111138553B (en) | 2020-01-17 | 2020-01-17 | Fusion protein, toxoplasma subunit vaccine and vaccine composition thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111138553A true CN111138553A (en) | 2020-05-12 |
CN111138553B CN111138553B (en) | 2020-09-25 |
Family
ID=70525722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010051245.2A Active CN111138553B (en) | 2020-01-17 | 2020-01-17 | Fusion protein, toxoplasma subunit vaccine and vaccine composition thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111138553B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112279925A (en) * | 2020-02-13 | 2021-01-29 | 北京海木集团有限公司 | Fusion protein, canine toxoplasma subunit vaccine and vaccine composition thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1407105A (en) * | 2001-09-13 | 2003-04-02 | 中国人民解放军第一军医大学 | Toxoplasmosis composite multi-position genes |
US7176286B2 (en) * | 2002-03-21 | 2007-02-13 | Kenton S.R.L. | Antigen fragments for the diagnosis of Toxoplasma gondii |
CN101070348A (en) * | 2006-05-12 | 2007-11-14 | 北京宝麦德生物医药科技有限责任公司 | O-type foot-and-mouth disease virus multi-epitope mucous membrane immunization vaccine and use |
CN105561343A (en) * | 2016-02-04 | 2016-05-11 | 山东大学 | DNA vaccine for preventing toxoplasmosis of humans or animals |
CN107533058A (en) * | 2015-03-01 | 2018-01-02 | 免疫阵列有限公司 | Use albumen, peptide and oligonucleotides diagnostic antigen systemic loupus erythematosus |
-
2020
- 2020-01-17 CN CN202010051245.2A patent/CN111138553B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1407105A (en) * | 2001-09-13 | 2003-04-02 | 中国人民解放军第一军医大学 | Toxoplasmosis composite multi-position genes |
US7176286B2 (en) * | 2002-03-21 | 2007-02-13 | Kenton S.R.L. | Antigen fragments for the diagnosis of Toxoplasma gondii |
CN101070348A (en) * | 2006-05-12 | 2007-11-14 | 北京宝麦德生物医药科技有限责任公司 | O-type foot-and-mouth disease virus multi-epitope mucous membrane immunization vaccine and use |
CN107533058A (en) * | 2015-03-01 | 2018-01-02 | 免疫阵列有限公司 | Use albumen, peptide and oligonucleotides diagnostic antigen systemic loupus erythematosus |
CN105561343A (en) * | 2016-02-04 | 2016-05-11 | 山东大学 | DNA vaccine for preventing toxoplasmosis of humans or animals |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112279925A (en) * | 2020-02-13 | 2021-01-29 | 北京海木集团有限公司 | Fusion protein, canine toxoplasma subunit vaccine and vaccine composition thereof |
CN112279925B (en) * | 2020-02-13 | 2021-07-13 | 北京海木集团有限公司 | Fusion protein, canine toxoplasma subunit vaccine and vaccine composition thereof |
Also Published As
Publication number | Publication date |
---|---|
CN111138553B (en) | 2020-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103172749B (en) | Preparation of African swine fever protein engineering vaccine | |
CN113058032B (en) | Classical swine fever, porcine pseudorabies and porcine circovirus type 2 triple subunit vaccine and preparation method and application thereof | |
CN110358742A (en) | 2 porcine circovirus b type and the divalent subunit vaccine of 2d type and preparation method thereof | |
CN104628865B (en) | A kind of pseudo- mad dog epitope polypeptide recombinant vaccine | |
CN102276730A (en) | Preparation method for staphylococcus aureus Iron-regulated surface determinant B immunodominant fragment (IsdBid)-target of RNAIII activating protein (TRAP) fusion protein and application thereof | |
CN104628871B (en) | A kind of preparation for recombinating bursal disease protein engineering vaccine | |
CN106434728A (en) | Recombinational bacillus subtilis of expressing highly pathogenic avian influenza H5N1 hemagglutinin HA protein | |
CN106279431B (en) | A kind of pig circular ring virus subunit inactivated vaccine | |
CN109021115B (en) | Porcine circovirus trivalent subunit vaccine | |
CN111138553B (en) | Fusion protein, toxoplasma subunit vaccine and vaccine composition thereof | |
EP3838916A1 (en) | Vaccine used for preventing toxoplasma gondii infection and preparation method therefor | |
CN117431200A (en) | Recombinant bacillus subtilis for displaying Newcastle disease virus HN protein on spore surface, construction method and application | |
CN111973738A (en) | Nucleic acid and recombinant protein co-immune vaccine based on hog cholera virus gene, preparation method and application | |
CN112279925B (en) | Fusion protein, canine toxoplasma subunit vaccine and vaccine composition thereof | |
CN103127498A (en) | Recombination antigen composition, vaccine and carrier and method for preparing antigen composition | |
CN102847168B (en) | The design of a kind of nucleic acid vaccine PV-Fn preventing bovine mastitis and structure thereof | |
CN109053896A (en) | A kind of pig circular ring virus bivalent genetic engineering vaccine | |
CN105566449B (en) | A kind of vaccine composition of resistant to foot and mouth disease and its preparation method and application | |
CN102372766B (en) | O-type foot-and-mouth disease multi-epitope vaccine | |
CN106397563A (en) | Nucleotide sequence for preventing sheep toxoplasmosis infection, vector, protein, vaccine, preparation method and application thereof | |
CN110092840A (en) | A kind of infectious laryngotracheitis of chicken, egg drop syndrome bigeminy polyepitope vaccines | |
CN110041410A (en) | Transmissible gastro-enteritis virus novel gene engineering subunit vaccine | |
CN114395052B (en) | Recombinant avian influenza trivalent vaccine and preparation method and application thereof | |
CN113122514B (en) | Echinococcus granulosus 3-hydroxyacyl-CoA dehydrogenase protein and application thereof | |
CN113372453B (en) | Fusion protein and porcine epidemic diarrhea virus S1 protein recombinant subunit vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |